DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/qj34l8/pharmapoint) has announced the addition of the "PharmaPoint: Chronic Heart Failure - Germany Drug Forecast and Market Analysis to 2022" report to their offering.
PharmaPoint: Chronic Heart Failure - Germany Drug Forecast and Market Analysis to 2022. The chronic heart failure (CHF) market is a mature market that has been slowly overtaken by generic drugs, and more branded products are expected to lose market exclusivity during the next few years. GlobalData predicts that the major global barriers that will play a crucial role in narrowing the global growth of the CHF market over the forecast period include the sparsely populated CHF pipeline and an increasing number of generic competitors in a market that is already heavily laden with generic drugs. However, the market entry of entry of Novartis' LCZ-696, the first novel, branded CHF drug to enter the market in five years, will noticeably enhance the overall market size during the forecast period. LCZ-696 is currently being evaluated in a trial for patients with heart failure with reduced ejection fraction (HF-REF), but if clinical trial data continue to demonstrate the drug's efficacy in patients with heart failure with preserved ejection fraction (HF-PEF), and it gains approval for use in this population, it will be the first drug to show efficacy in this largely underserved patient population. In addition, increased use of MRAs over the forecast period in all seven major markets (7MM) will contribute to the increase in the global CHF market size.
GlobalData anticipates that this growth in the German CHF market will be the result of the market entry of a novel treatment, LCZ-696, and an increase in the use of MRAs over the forecast period. LCZ-696 has the potential to replace ACE inhibitors in the treatment of CHF. LCZ-696 is a combination drug, with Diovan as one of its ingredients; therefore, it is reasonable to expect that LCZ-696 will also steal patient share from Diovan and other ARBs, which are given to patients who cannot tolerate ACE inhibitors.
Scope
- Overview of CHF including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Germany including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Germany from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting Germany CHF market.
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Disease Overview
4 Disease Management
4.1 Treatment Overview
4.2 Germany
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Drug Profiles
6 Opportunity and Unmet Need
6.1 Overview
6.2 Lack of Therapies for HF-PEF Patients
6.3 Lack of Therapies for Patients with Renal Impairment
6.4 Diagnosis of Asymptomatic Left Ventricular Dysfunction
6.5 Treatment of Patients with Multiple Comorbidities
6.6 Increase in Survival of CHF Patients
6.7 Unmet Needs Gap Analysis
6.8 Opportunity: Treatment of Patients with HF-PEF
6.9 Opportunity: Therapies for Patients with Renal Impairment and Multiple Comorbidities
6.10 Opportunity: New Drugs that Show Increase in Survival of CHF Patients
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development
8 Market Outlook
9 Appendix
For more information visit http://www.researchandmarkets.com/research/qj34l8/pharmapoint
